Combination strategies for advanced-stage urothelial carcinoma: a paradigm shift
- 26 January 2024
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 21 (4) , 255-256
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial CarcinomaNew England Journal of Medicine, 2023
- LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)Annals of Oncology, 2023
- 658MO Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)Annals of Oncology, 2021
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2021
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial CarcinomaNew England Journal of Medicine, 2020
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trialThe Lancet, 2020
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaNew England Journal of Medicine, 2017
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986Journal of Clinical Oncology, 2012
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005